AstraZeneca reports total voting rights as of February end

AstraZeneca PLC (LSE:LON:AZN), a leading biopharmaceutical company with a market capitalization of $235 billion, disclosed its total number of voting rights in a recent regulatory filing. As of February 28, 2025, the company’s issued share capital comprised 1,550,607,175 ordinary shares, each with a nominal value of US$0.25. According to InvestingPro analysis, the stock is currently trading below its Fair Value, with strong financial health metrics. Notably, AstraZeneca (NASDAQ:AZN) confirmed that no shares are currently held in Treasury.

This figure represents the total voting rights in the company and serves as a key metric for shareholders. It is essential for calculations related to notifications that shareholders may be required to make under the UK Financial Conduct Authority’s Disclosure and Transparency Rules. These rules mandate shareholders to disclose their interest in, or changes to their interest in, the company.

AstraZeneca, headquartered in Cambridge, UK, specializes in the discovery, development, and commercialization of prescription medicines. The company focuses on three main therapy areas: Oncology, Rare Diseases, and BioPharmaceuticals, which includes Cardiovascular, Renal & Metabolism, and Respiratory & Immunology sectors. AstraZeneca’s products are available in over 125 countries and are utilized by millions of patients globally.

The information disclosed is based on a press release statement from AstraZeneca PLC, filed with the Securities and Exchange Commission. The company, which is listed on the London, Stockholm, and Nasdaq stock exchanges, has not held any shares in Treasury, which implies that all the issued shares are available to be voted on by shareholders.

The announcement is a routine disclosure that publicly traded companies are required to make periodically to keep investors informed about potential changes in voting power. The company’s secretary, Adrian Kemp, signed off on the report, emphasizing AstraZeneca’s commitment to transparency in its corporate governance practices.

In other recent news, AstraZeneca has reported significant developments in its breast cancer treatment portfolio. The company announced positive results from the SERENA-6 Phase III trial, where its investigational drug camizestrant, in combination with CDK4/6 inhibitors, showed improved progression-free survival for patients with advanced breast cancer. This trial highlights a potential shift in first-line treatment strategies, especially for those with ESR1 mutations. Additionally, AstraZeneca’s Enhertu received a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use, recommending its approval for certain breast cancer patients in the EU. This recommendation is based on the DESTINY-Breast06 Phase III trial results, which showed a significant reduction in disease progression risk.

In financial news, Moody’s upgraded AstraZeneca’s senior unsecured ratings from A2 to A1, citing the company’s robust growth in organic revenues and a strong product pipeline. The company’s revenue grew by 21% at constant exchange rates in 2024, driven by its BioPharmaceuticals and Oncology sectors. Moreover, AstraZeneca has agreed to acquire FibroGen (NASDAQ:FGEN)’s China subsidiary for approximately $160 million, a move expected to enhance FibroGen’s financial position and extend its cash runway. This acquisition will also grant AstraZeneca all rights to roxadustat in China, a leading treatment for anemia in chronic kidney disease. These recent developments underscore AstraZeneca’s ongoing efforts to advance its oncology pipeline and expand its market presence globally.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.